Press Releases

69_IGC-Pharma-to-Host-Mid-Year-Fiscal-2026-Shareholder-Update-Call-on-November-17,-2025
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
Read More →
68_IGC-Pharma-Expands-its-AI-Powered-Drug-Discovery-In-Silico-Pipeline
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
Read More →
67_IGC-Pharma-Advances-to-Semi-Finals-in-the-Alzheimer’s-Insights-AI-Prize-with-“AHA--Agentic-Harmonization-Assistant”
IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant” 
Read More →
66_IPhase-2-CALMA-Clinical-Trial-to-University-of-South-Florida’s-
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences 
Read More →
65_Results-2025
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
Read More →
64_IGC-Pharma’s-Preclinical-Data-for-IGC-1C-
IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease 
Read More →
63_IGC-Pharma-Adds-Ichor-Research-as-New-Site-for-CALMA
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial 
Read More →
61_IGC-Pharma-Announces-New-Preclinical-Data-Demonstrating-TGR-63’s (1)
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology 
Read More →
61_IGC-Pharma-Achieves-50-Patient-Enrollment-Milestone
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial
Read More →
60_GC-Pharma,-Inc.-Receives-Recognition-for-Excellence-in-Code-Clarity,-Reproducibility (1)
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer’s Detection 
Read More →
59_IGC-Pharma-Expands-CALMA-Phase-2-Trial-to-Island-Health’s
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada 
Read More →
58_IGC-Pharma-receives-Notice-of-Allowance-for-Novel-THC
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette’s Syndrome 
Read More →
57_IGC-Pharma-Announces-Coverage-Report-by-Ascendiant-Capital-Marketsjpg
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50.” 
Read More →
56_IGC-Pharma-Expands-CALMA-Phase-2-Trial
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City 
Read More →
55_IGC-Pharma-Reports-First-Quarter-Fiscal-2026-Financial-Results
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial
Read More →
54_IGC-Pharma-Unveils-Groundbreaking-Preclinical--in-vitro
IGC Pharma Highlights Alzheimer’s Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 
Read More →